BioCentury
ARTICLE | Company News

NICE's managed access deal for Spinraza could signal more flexibility on orphan drugs

May 15, 2019 8:51 PM UTC

Spinal muscular atrophy patients in England and Wales can now begin to access Spinraza nusinersen after NICE reached a deal with Biogen to provide the drug through a managed access program.

NHS England will begin funding Spinraza treatment for a five-year term and will also collect data on the drug's effectiveness. Biogen Inc. (NASDAQ:BIIB) will immediately make Spinraza available to SMA type 1 patients, and NHS will roll the therapy out to SMA types 2 and 3 patients after NICE publishes its final appraisal determination on May 31...